Abstract
Conclusion
Neither phenylbutazone nor probenecid caused a statistically significant uricosuria in 2 patients with rheumatoid arthritis, even though these drugs decreased the pool size of uric acid, increased the turnover rate, and decreased the serum urate level. In 3 gouty patients and 1 rheumatoid arthritis patient with an elevated serum urate concentration the drugs caused statistically significant uricosuria but variable effects on the pool size, turnover rate and serum urate concentration. In 1 patient with rheumatoid arthritis the results were equivocal. In 4 of these 5 cases the uricosuric effect of probenecid was statistically greater than that of phenylbutazone. It is postulated that the uricosuric drugs such as phenylbutazone and probenecid will produce statistically significant uricosuria only in those cases in which increased body stores of uric acid are present. The present studies are based on experimental periods of 1-2 weeks for each regimen and the data do not indicate what happens in the first few hours of drug administration.
Get full access to this article
View all access options for this article.